Heinrich, Maria http://orcid.org/0000-0002-4530-7343
Spies, Claudia http://orcid.org/0000-0002-1062-0495
Borchers, Friedrich http://orcid.org/0000-0001-7290-2271
Feinkohl, Insa http://orcid.org/0000-0002-0307-1862
Pischon, Tobias http://orcid.org/0000-0003-1568-767X
Slooter, Arjen J. C. http://orcid.org/0000-0003-0804-8378
von Haefen, Clarissa http://orcid.org/0000-0001-5740-1794
Zacharias, Norman http://orcid.org/0000-0001-5794-5716
Winterer, Georg http://orcid.org/0000-0002-3610-5029
Lammers-Lietz, Florian http://orcid.org/0000-0002-7371-3947
Funding for this research was provided by:
Berlin Institute of Health (Digital Clinician Scientist Program)
European Commission (602461, 602461, 602461, 602461)
Charité - Universitätsmedizin Berlin
Article History
Received: 26 March 2023
Accepted: 18 February 2024
First Online: 14 March 2024
Declarations
: Dr. Maria Heinrich and Dr. Florian Lammers-Lietz are the guarantors who take responsibility for the published work.
: The study protocol was approved by the local ethics committees of the two enrolling study centers in Berlin, Germany (EA2/092/14), and Utrecht, Netherlands (14–469), and conducted in accordance with the declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The study has been registered at clinicaltrials.gov (NCT02265263) on Oct 15, 2014.
: All patients gave written informed consent prior to inclusion in the BioCog study. Patients who were unable to understand written or verbal study information provided by the study physician were excluded from participation.
: Dr. Heinrich reports grants from the BIH Charité Clinician Scientist Program during the conduct of the BioCog study. Dr. Lammers-Lietz reports personal fees from PharmaImage GmbH during the conduct of the BioCog study. Dr. Winterer is currently licensing a Class IIa medical device (web-based software tool for multivariate risk prediction of POD and POCD in clinical practice). This diagnostic software includes a pending patent application. Dr. Winterer founder and CEO of PharmaImage Biomarker Solutions GmbH Berlin (Germany) and President of its subsidary Pharmaimage Biomarkers Incl. (Cambridge, MA, USA) and PI Health Solutions GmbH Berlin (Germany). Prof. Winterer reports grants from the Deutsche Forschungsgemeinschaft/German Research Society and from the German Ministry of Health. Prof. Spies reports grants from the European Commission, from Drägerwerk AG & Co. KgaA, Deutsche Forschungsgemeinschaft/German Research Society, Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR)/German Aerospace Center, Einstein Stiftung Berlin/Einstein Foundation Berlin, Gemeinsamer Bundesausschuss/Federal Joint Committee (G-BA), Inneruniversitäre Forschungsförderung/Inner University Grants, Projektträger im DLR/Project Management Agency, Stifterverband für die deutsche Wissenschaft e.V./Non-Profit-Society Promoting Science and Education, European Society of Anaesthesiology and Intensive Care, personal fees from Georg Thieme Verlag, grants from Dr. F. Köhler Chemie GmbH, Sintetica GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Medtronic, Federal Joint Committee (Gemeinsamer Bundesausschuss). She has patents 10 2014 215 212.7, 50 2015 010 347.7, 50 2015 010 534.8, 10 2018 110 275.5, 10 2018 114 364.8, 10 2014 215 211.9, 3 174 588 PCT/EP 2015/067731 and 15753 627.7 licensed. Prof. Spies participates in the AWMF (Association of the Scientific Medical Societies in Germany (unpaid), Deutsche Forschungsgemeinschaft/German Research Society review board (unpaid) and Deutsche Akademie der Naturforscher Leopoldina e.V./German National Academy of Sciences Leopoldina (unpaid).